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Objective: To determine the feasibility of visual inspection with the use of acetic acid (VIA) 
as a screening method for cervical cancer, an alternative to the Pap smear used in primary health 
care setting in Sudan, and to compare sensitivity, specificity, positive and negative predictive 
values, and histological diagnosis of positive cases of both tests.
Methods: A cross-sectional study of 934 asymptomatic women living in Khartoum, Sudan, 
was conducted during 2009–2010. A semi-structured questionnaire containing socio-economic 
and reproductive variables was used to collect data from each participant. Methods of screening 
used were VIA and conventional Pap smear, followed by colposcopy and biopsy for confirma-
tion of the positive results of both screening tests.
Results: The tests identified altogether 119 (12.7%) positive women. VIA detected significantly 
more positive women than Pap smear (7.6% versus 5.1%; P = 0.004), with an overlap between 
the two screening tests in 19% of positive results. There was no significant difference between 
VIA and Pap smear findings and sociodemographic and reproductive factors among screened 
women. Use of colposcopy and biopsy for positive women confirmed that 88/119 (73.9%) 
were positive for cervical intraepithelial neoplasia. VIA had higher sensitivity than Pap smear 
(74.2% versus 72.9%; P = 0.05) respectively. Out of 88 confirmed positive cases, 22 (25.0%) 
cases were invasive cervical cancer in stage 1, of which 19 versus three were detected by VIA 
and Pap smear respectively (P = 0.001). VIA had higher sensitivity and lower specificity than 
Pap smear (60.2% versus 47.7%) and (41.9% versus 83.8%) respectively. The combination of 
VIA/Pap has better sensitivity and specificity than each independent test (82.6% and 92.2%).
Conclusion: The findings of this study showed that VIA has higher sensitivity and lower 
specificity compared to Pap smear, but a combination of both tests has greater sensitivity and 
specificity than each test independently. It indicates that VIA is useful for screening of cervical 
cancer in the primary health care setting in Sudan, but positive results need to be confirmed by 
colposcopy and biopsy.
Keywords: cervical, cancer, screening, VIA, Pap smear, colposcopy, sensitivity, specificity, 
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Introduction
Cervical cancer is the third most common cancer in women, and the seventh of 
overall cancers worldwide, with an estimated 529,000 new cases in the year 2008.1 
It has been estimated that more than 87% of the global burden occurs in developing 
countries, where it accounts for 13% of all female cancers. High-risk regions include 
the Eastern and Western Africa regions.1 In Sudan cervical cancer ranks as the second 
most common cancer among women with age-standardized incidence of 15 per 100,000 
and age-standardized mortality of 25 per 100,000.2
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Substantial reduction in cervical cancer will only be 
realized if sustainable cervical cancer screening programs 
are implemented on a global scale to assure early detection 
and treatment of precancerous lesions. Effective programs 
must meet three targets: at least 70% of the targeted popula-
tion should be screened at least once in a lifetime; screen-
ing assays and diagnostic tests must be reproducible and 
sufficiently sensitive; and specificity for the detection of 
high-grade precursor lesions and effective treatment must 
be provided.3
Screening with use of Pap smear and liquid-based 
  cytology has contributed significantly to the reduction of 
cervical cancer in developed countries.4 In addition, screen-
ing for human papillomavirus with use of DNA testing has 
proven useful in early detection of the disease.5 Nevertheless, 
these methods of screening are very difficult to implement 
in low-resource countries due to the lack of laboratory infra-
structure and trained professionals. Therefore there is a vital 
need for alternative preventive methods for cervical cancer 
in developing countries.6
Recently, interest in visual inspection with acetic acid 
(VIA) has increased. Numerous studies have been conducted 
on its accuracy and its ability to detect cervical lesions when 
compared with other techniques, both conventional and non-
conventional.7 VIA has emerged as a promising screening 
method alternative to cytology based methods. This test is 
easy, cost-effective, and fits well to low resource countries.8 
VIA is based on the premise that the majority of preinvasive 
and invasive cervical lesions are visible on examination by 
the naked-eye after application of acetic acid. It involves 
insertion of a vaginal speculum and application of 3%–5% 
acetic acid solution using a cotton swab. After 5 minutes, the 
cervix is inspected under illumination of a halogen lamp. If 
there is an acetowhitening area present, the result of the test is 
positive. The test is negative when there is no acetowhitening 
area. The normal squamous epithelium tissue of the cervix 
is pink. On application of acetic acid, cervical intraepithelial 
neoplasia (CIN) lesion takes on a white color due to the 
increased precipitation of nuclear proteins and cytokeratins 
in the cervical epithelium.9
This study aimed to determine feasibility of the VIA 
screening method for cervical cancer as an alternative to a 
Pap smear in the primary health care setting in Sudan, and 
to compare performance of VIA and Pap smear.
Materials and methods
A cross-sectional study of 1250 asymptomatic women   living 
in Khartoum, Sudan, was conducted in primary health care 
centers in Khartoum State, Sudan, during the period of 
December 2009 to April 2010. Healthy married women 
aged 25–50 years, living in Khartoum State and who were 
  willing to participate in screening, were included in the study. 
Pregnant women, women with absent menstrual periods, and 
women with a previous history of cervical cancer, abnormal 
cytology, or hysterectomy, were excluded from the study.
Eligible women were included in the study after they were 
given information about the study’s objectives, screening test 
procedures, and the benefits to be gained from screening. 
The women who agreed to participate in the study provided 
  written consent. A questionnaire focusing on sociodemo-
graphic, obstetrics and gynecological variables, and other risk 
factors was filled in by each participant with the assistance 
of registered nurses. The women then underwent a complete 
physical and gynecological examination, and pelvic assess-
ment performed by a physician trained in early detection 
of cancer. The Pap smear sampling and VIA testing were 
performed by the same physician.
The VIA test was performed by application of 3%–5% 
acetic acid into the cervix uteri by using sterile forceps 
and a small piece of cotton. After 5 minutes a naked-eye 
assessment was performed under direct illumination of a 
100-watt halogen lamp. A positive VIA test was defined 
as well-marginated, raised, opaque, acetowhite lesion(s) 
observed on the cervix uteri within the squamo-columnar 
junction zone (the region in the uterine cervix in which the 
squamous lining of the vagina is replaced by the columnar 
epithelium typical of the body of the uterus and which is a 
common site of neoplastic change).10
The Pap smear sample was obtained by using a spatula. 
The Pap smear was fixed with ethanol for 30 minutes and sent 
to a cytologist for investigation. The cytological results of the 
Pap smear were reported according to the Bethesda System.10 
Positive cytology diagnosis was considered when any of these 
pathological changes were detected: a typical squamous cell 
of undetermined significance, CIN, or invasive cancer.
Figure 1 demonstrates the flow chart of the study. The 
total number of women who were invited to participate 
in the study was 1250. Of them, 985 women agreed to 
  participate, giving a response rate of 79%. Of the total num-
ber of responding women, 51 (5.2%) were excluded due to 
  varying reasons: 25 had an absence of menstrual periods, 
16 were not sure about their last menstrual period, three had 
a   previous history of cervical cancer treatment, and 6 were 
under   fertility treatment.
Women with positive VIA or positive Pap smears were 
referred to a gynecological oncologist at a specialized 
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  oncology center for colposcopy and biopsy. The obtained 
biopsies were examined by a histopathologist for confirma-
tion of the results of both screening tests. The histopatholo-
gist was blinded to the results of the screening tests. The 
time interval between the screening test and colposcopy was 
2–12 days for women with positive VIA and 7–21 days for 
women with a positive Pap smear; the delay of Pap smear 
results was due to the laboratory process, which took a longer 
time to investigate the smear specimens.
Data analysis
Data were entered into STATA (v9.2; Stata Corp, College 
Station, TX). Descriptive statistics were used to analyze the 
demographic data and to compare the results of both   screening 
tests. t-tests were used to detect any significant   difference 
between continuous variables (age, age of   becoming sexually 
active, and number of deliveries). The Chi squared test was 
used to detect any significant difference between categorical 
variables and positive results of VIA and Pap smear tests in 
the screened women in each group. Sensitivity, specificity, 
positive and negative predictive values were compared for 
both screening tests. P value and 95% confidence intervals 
are reported.
Results
The number of women who fulfilled the eligibility criteria, 
offered informed consent, and agreed to participate in the 
study, was 934 (95% of total number of the respondents).
The mean age of the eligible 934 participants was 34.8 years 
for those that screened negative and 32.8 years for those   
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Women invited for participation (n = 1250) 
985 (79%) respondents 265 (21%) non-respondents  
934 (98%) eligible  51 (2%) not eligible 
Screening with VIA and Pap smear 
71 (7.6%) VIA positive 24 (2.6%) VIA and Pap positive  48 (5.1%) Pap positive 815 (87.3%) negative  
Colposcopy and biopsy 
Positive  
53 (74.6%) 
Negative
36 (25.4%) 
Negative
13 (27.1%)
Positive
35 (72.9%)
Positive  
19 (79.2%) 
Negative
5 (20.8%) 
86 (9.2%) cervical infection 
(treated and screened after completion of
treatment within 2 weeks) 
848 (90.8%) healthy 
Colposcopy and biopsy  Colposcopy and biopsy 
Figure 1 Flow chart of the study.
Abbreviation: VIA, visual inspection with the use of acetic acid.International Journal of Women’s Health 2012:4
that screened positive (Table 1). The respective ages of sexual 
initiation were 20.3 years and 19.8 years. The number of deliv-
eries ranged from one to seven live births, with a mean of two 
births for the study sample; 35.2% were nulliparous. The main 
education level was primary school, and the majority of partici-
pating women were principally unpaid domestic   workers. The 
place of residence was urban for 62.1%, and rural for 37.9% of 
the women. Almost 90% of screened women had gone through 
genital mutilation. The majority of women (76%) in the study 
sample used an oral contraceptive pill, and 76% of women had 
an episiotomy during vaginal delivery (Table 1).
All women had undergone counseling and clinical 
assessment before screening; 86 (9.2%) of them had signs of 
cervical infection such as chlamydia, bacterial, and Candida 
albican infections. They received appropriate treatment and 
were screened 2 weeks after recovering from infection.
The results of all screened women revealed that 71 (7.6%) 
women were positive when VIA tested, and according to the 
later Pap smear results 48 (5.1%) were positive (Table 2). 
There was an overlap between VIA and Pap smear in positive 
results of 24 samples.
Comparisons between the study sample characteristics, 
VIA test positive results, and Pap smear positive results 
revealed that there was a significant difference in the age of 
women who tested positive by VIA and Pap smear (mean 
age 32.3 years versus 38.3 years, respectively). There 
was a significant difference between positive results of 
VIA and Pap smear in relation to women who had gone 
through female genital mutilation (93.0% versus 79.2%; 
P = 0.05). There was also a significant difference between 
women who had cervical infection and positive results of 
VIA versus Pap smear (33.9% versus 54.2%; P = 0.04; 
Table 2).
The results of histopathology revealed that 88 of 119 
(73.9%) confirmed positive, of which 53 of 71 (74.6%) had 
a positive VIA and 35 (72.9%) had a positive Pap smear. 
Moreover, classification of the positive specimens showed 
that (75%) of cases were CIN and (25%) were in Stage 1. 
The categories of histopathological findings differed based 
on the screening test, VIA significantly detected more cases 
in stage 1 than Pap smears (19 versus 3; P = 0.001; Table 3). 
There were 24 overlapping positive cases of VIA and Pap 
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Table 1 Characteristics of the participants in the screening for cervical cancer by VIA and Pap smear in Khartoum
Variable Total  
(n = 934)
Screening P value
Negative (n = 815) Positive (n = 119)
Age, years (mean ± SD) 34.9 ± 7.6 34.8 ± 7.6 32.8 ± 7.6 0.007
Age of sex initiation, years (mean ± SD) 20.1 ± 2.1 20.3 ± 2.0 19.8 ± 1.9 0.01
number of deliveries (mean ± SD) 1.81 ± 2.3 1.71 ± 1.8 1.92 ± 2.1 0.2
Education level
  no formal education 247 (26.4%) 216 (26.5%) 31 (26.0%) 0.01
  Basic school 687 (73.6%) 599 (73.5%) 88 (74.0%)
Employment
  Employed 338 (36.2%) 286 (35.1%) 52 (43.7%) 0.3
  Unemployed 596 (63.8%) 529 (64.9%) 67 (56.3%)
Residence
  Rural 354 (37.9%) 314 (38.5%) 40 (33.6%) 0.08
  Urban 580 (62.1%) 501 (61.5%) 79 (66.4%)
Female genital mutilation
  Yes 836 (89.5%) 732 (89.8%) 104 (87.4%) 0.5
  no 98 (10.4%) 83 (10.2%) 15 (12.6%)
Contraceptive use
  Yes 710 (76.0%) 620 (76.1%) 90 (10.4%) 0.9
  no 224 (24.0%) 195 (23.9%) 29 (3.1%)
Delivery type
  nulliparous 329 (35.2%) 281 (34.5%) 48 (40.3%) 0.2
  Parous 605 (64.8%) 534 (65.5%) 71 (59.7%)
Episiotomy
  Yes 710 (76.0%) 624 (76.6%) 86 (72.3%) 0.3
  no 224 (24.0%) 191 (23.4%) 33 (27.7%)
Cervical infection
  no infection 848 (90.8%) 779 (95.6%) 69 (58.0%) 0.0001
  Infected 86 (9.2%) 36 (4.4%) 50 (42.0%)
Abbreviations: SD, standard deviation; VIA, visual inspection with the use of acetic acid.International Journal of Women’s Health 2012:4
smear, of which 52.6%, 31.6%, 10.5%, and 5.3% were CIN1, 
CIN2, CIN3, and stage 1, respectively.
Comparison of the performance of two VIA and Pap 
smears in terms of sensitivity and specificity, and in posi-
tive and negative predictive values brought varied results 
(Table 4). VIA had higher sensitivity than Pap smear but 
lower specificity. VIA/Pap combined had higher sensitivity 
and specificity than VIA and Pap smear alone.
Discussion
African countries rank second highest for morbidity and 
mortality of cervical cancer after Asia.1 Sudan occupies 
the top level of cervical cancer morbidity and mortality in 
northern African countries.2 In these countries there are no 
screening programs, or the programs are ineffectively devel-
oped and poorly organized. The majority of the screening 
programs are using the Pap smear method and attempt to 
imitate the excellent outcome achieved in developed coun-
tries (Finland is the best worldwide example for decrease 
in cervical cancer incidence as a result of a well-organized 
screening program).27 Nevertheless, the results of these 
programs have been very poor due to lack of infrastructure, 
inadequate training for medical staff, poor organization, 
lower coverage of women at risk, no standardized quality 
control systems, and a lack of follow-up and treatment 
of positive cases.12 Therefore, in recent years, screening 
using a new method has emerged as an alternative to the 
conventional Pap smear, which involves visual inspection 
with use of acetic acid.7
VIA has become a promising alternative for develop-
ing countries because it is inexpensive, rapid, requires 
brief training, and does not require laboratory equipment. 
A number of earlier studies have reported that VIA has a 
comparable or superior result to Pap smears in the detection 
of cervical cancer.8
This is the first study carried out to determine the fea-
sibility of VIA as a screening method for cervical cancer 
in the primary health care setting in Sudan. The study 
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Table 2 Comparison between positive VIA, Pap smear tests, and characteristics of participants in Khartoum (n = 934)
Variable category All test positive Screening test P value
VIA Pap smear
number (%) of screening positive 119 (12.7%) 71 (7.6%) 48 (5.1%) 0.004
Continuous variable (Mean ± SD) (Mean ± SD) (Mean ± SD)
Age, years (mean ± SD) 32.8 ± 7.6 32.3 ± 6.7 38.3 ± 6.3 0.0001
Age of sex initiation, years (mean ± SD) 19.8 ± 1.9 19.8 ± 1.9 20.3 ± 2.0 0.1
number of deliveries (mean ± SD) 1.92 ± 2.1 1.71 ± 2 1.92 ± 2.3 0.5
Categorical variables n (%) n (%) n (%)
Education level
  no formal education 31 (26.0) 19 (26.8) 12 (25.0) 0.9
  Formal education 88 (55.5) 52 (54.9) 36 (65.3)
Employement
  Employed 52 (43.7) 29 (40.8) 23 (47.9) 0.5
  Unemployed 67 (56.3) 42 (59.1) 25 (52.1)
Residence
  Rural 40 (33.6) 23 (32.4) 17 (35.4) 0.8
  Urban 79 (66.4) 48 (67.6) 31 (64.6)
Female genital mutilation
  Yes 104 (87.4) 66 (93.0) 38 (79.2) 0.05
  no 15 (12.6) 5 (7.0) 10 (20.8)
Contraceptive use
  Yes 90 (10.4) 55 (77.5) 35 (72.9) 0.08
  no 29 (3.1) 16 (22.5) 13 (27.1)
Delivery type
  nulliparous 46 (38.7) 30 (42.3) 16 (33.3) 0.9
  Parous 73 (59.7) 41 (57.7) 32 (66.7)
Episiotomy 
  Yes 86 (72.3) 55 (77.5) 31 (64.6) 0.8
  no 33 (27.7) 16 (22.5) 17 (35.4)
Cervical infection
  no infection 69 (58.0) 47 (66.1) 22 (45.8) 0.04
  Infected 50 (42.0) 24 (33.9) 26 (54.2)
Abbreviations: SD, standard deviation; VIA, visual inspection with the use of acetic acid.International Journal of Women’s Health 2012:4
was preceded by a pilot study which showed that 16% of 
screened women were positive when screened by VIA.13 
The result of the final study is lower (7.6%). This difference 
could be due to sampling variation and the selected study 
population criteria. The findings of this study revealed 
that VIA detected significantly more positive women than 
Pap smears (7.6% versus 5.1%; P = 0.004) with an overlap 
between the two screening tests in 19% of positive results. 
VIA had higher sensitivity and positive predictive values 
than Pap smears but lower specificity and negative predic-
tive values, respectively. VIA detected more confirmed 
diagnosed cases of intraepithelial cervical intraepithelial 
neoplasia than Pap smears; however, the difference was 
not statistically significant and in the confirmed diagnosed 
cases of invasive cervical cancer in stage 1, VIA detected 
significantly more cases than Pap smears (35.8% versus 
8.6%; P = 0.001).
The result of screened-positive women by VIA in this 
study (7.6%) was higher than that found in Bangladesh 
(4.8%)14 and in Angola (6.6%),15 but lower than in Kenya 
(13.9%)16 or in Honduras (14%),17 and it was much lower 
than found in El Salvador (26.5%),18 or in Thailand 
(38.1%).19
In our study the sensitivity of VIA was 60.2%. This 
finding is similar to that reported in Tanzania (60.6%),20 
higher than in Colombia (53.6%),21 but lower than in India 
(80.0%),22 in Angola (70.7%),15 and, again, in India (98%).23   
Sensitivity and specificity of the VIA test in this study was 
consistent with pooled VIA sensitivity that was described by 
an International Agency on Research for Cancer multicenter 
study in India and Africa.24 The specificity of the VIA test 
in our study was 42%; it was lower compared to Pap smears 
(65%), and lower than found for VIA in Kenya (75%)25 and 
in Angola (94.5%).15
There was only a small (although marginally significant, 
P = 0.05) difference in the total proportion of confirmed 
cases by colposcopy (74.6% versus 72.9%) for VIA and 
Pap respectively. There was no significant difference in 
confirmed cases of CIN1, CIN2, and CIN3 among the 
VIA positive tests than among the Pap positive tests. In 
turn, VIA detected significantly more (P , 0.001) cases 
of cervical cancer in stage 1 (35.8%) than Pap smears 
(8.6%). The sensitivity value for VIA in our study is higher 
than that found by Basu et al in Calcutta, India; 74.6% and 
55.7%   respectively.26 In our study VIA detected more cases 
of CIN than Pap smear (36 versus 32). Nevertheless, the 
results of this study delineate the potential benefits of using 
VIA within the primary health care setting in low resource 
  countries. VIA increases detection of premalignant lesions 
of the cervix and diminishes the probability of women 
defaulting before they are appropriately followed-up and 
treated. We believe that VIA can be used as a screening tool 
in low resource countries, not only in the primary health 
care setting but also in general hospitals.
Table 4 Comparison of VIA and Pap smear tests performance in Khartoum (934 women)
VIA test 95% CI Pap smear 95% CI VIA/Pap 95% CI
Sensitivity 60.2 49.8–69.8 47.7 37.5–58.0 82.6 63.9–93.0
Specificity 41.9 26.4–59.2 83.8 68.9–92.3 92.2 83.0–96.6
Positive predictive value 74.6 63.3–83.3 87.5 75.3–94.1 79.2 59.5–90.8
negative predictive value 27.1 16.6–41.0 40.3 30.0–51.4 93.7 84.8–97.5
Abbreviations: CI, confidence interval; VIA, visual inspection with the use of acetic acid.
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Table 3 Comparison between VIA and Pap positive total women (n = 119) undergone colposcopy and histopathology
Total (%) VIA test 
n (%)
Pap smear 
n (%)
P value Overlap both VIA  
and Pap positive (%)
Total screened positive 119 71 (7.5) 48 (5.1) 0.004 24 (20.2)
Total confirmed by  
colposcopy and biopsy
88 (73.9) 53 (74.6) 35 (72.9) 0.05 19 (79.2)
Classification of confirmed positive
  CIn1 12 (13.6) 4 (7.5) 8 (22.9) 0.2* 10 (52.6)
  CIn2 26 (29.5) 14 (26.4) 12 (34.3) 0.7 6 (31.6)
  CIn3 28 (31.8) 16 (30.2) 12 (34.2) 0.4 2 (10.5)
  Stage 1 22 (25.0) 19 (35.8) 3 (8.6) 0.001* 1 (5.3)
Note: *Yates Chi-square test and P value.
Abbreviations: CIn, cervical intraepithelial neoplasia; VIA, visual inspection with the use of acetic acid.International Journal of Women’s Health
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Conclusion
The results of this study showed that VIA has higher sensitiv-
ity, but lower specificity, compared to Pap smears. A com-
bination of VIA/Pap increased sensitivity and specificity of 
detection of cervical cancer. The findings of the study indicate 
that VIA is useful for the screening of cervical cancer in the 
primary health care setting in Khartoum State, Sudan.
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